Onefund LLC Acquires 18 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Onefund LLC lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 947 shares of the medical equipment provider’s stock after acquiring an additional 18 shares during the period. Onefund LLC’s holdings in Intuitive Surgical were worth $494,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ISRG. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical during the fourth quarter valued at approximately $28,000. MidAtlantic Capital Management Inc. bought a new position in Intuitive Surgical during the third quarter valued at approximately $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical during the fourth quarter valued at approximately $36,000. Finally, Capital Performance Advisors LLP bought a new position in Intuitive Surgical during the third quarter valued at approximately $38,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.7 %

ISRG opened at $573.15 on Friday. The stock’s fifty day moving average is $569.87 and its two-hundred day moving average is $528.64. The company has a market capitalization of $204.14 billion, a P/E ratio of 89.42, a PEG ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00.

Analyst Ratings Changes

A number of brokerages recently commented on ISRG. Leerink Partners increased their price target on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Jefferies Financial Group increased their price target on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $522.00 to $650.00 in a research note on Monday, December 2nd. Truist Financial raised their price objective on Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a research note on Friday, January 24th. Finally, UBS Group raised their price objective on Intuitive Surgical from $500.00 to $560.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Insiders Place Their Bets

In other Intuitive Surgical news, CFO Jamie Samath sold 270 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $540.15, for a total transaction of $145,840.50. Following the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,730,093.55. This trade represents a 2.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 408 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the sale, the executive vice president now directly owns 353 shares in the company, valued at $208,181.75. This trade represents a 53.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,077 shares of company stock worth $4,620,025 in the last ninety days. 0.80% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.